Table 3.

AGT, AGTR1, ACE, and CYP11B2 gene polymorphisms with risk of different cause of ESRD.

	Diabetic nephropathy (n = 256) adjusted# OR (95% CI)	Hypertensive nephropathy (n = 84) adjusted# OR (95% CI)	Glomerulonephritis (n = 174) adjusted# OR (95% CI)	Systemic nephropathy (n = 66) adjusted# OR (95% CI)	Other&   (n = 67)   adjusted# OR (95% CI)
AGT
M235T
CT/CC	0.75 (0.52–1.09)	1.07 (0.58–1.98)	0.51 (0.31–0.85)*	0.97 (0.5–1.89)	1.08 (0.59–1.99)
TT/CC	0.33 (0.09–1.14)	—	0.18 (0.02–1.41)	—	0.46 (0.06–3.55)
T174M
CT/CC	1.26 (0.84–1.88)	1.10 (0.54–2.24)	1.07 (0.66–1.75)	0.79 (0.35–1.77)	1.17 (0.58–2.36)
TT/CC	0.94 (0.17–5.07)	—	0.94 (0.10–8.55)	2.58 (0.29–23.17)	2.13 (0.23–19.54)
AGTR1
A1166C
AC/AA	0.79 (0.42–1.47)	0.96 (0.37–2.51)	1.49 (0.81–2.74)	0.72 (0.22–2.43)	1.59 (0.68–3.74)
CC/AA	—	—	—	—	—
C573T
CT/CC	1.30 (0.92–1.83)	0.96 (0.54–1.70)	1.32 (0.87–1.98)	1.31 (0.69–2.49)	1.00 (0.54–1.84)
TT/CC	0.68 (0.33–1.39)	0.76 (0.26–2.25)	0.59 (0.24–1.46)	1.62 (0.61–4.35)	1.4 (0.55–3.58)
ACE
ID
ID/II	1.89 (1.31–2.71)*	1.16 (0.64–2.11)	1.35 (0.89–2.05)	0.83 (0.42–1.61)	1.22 (0.66–2.26)
DD/II	1.71 (0.97–3.00)	2.21 (1.01–4.83)*	1.03 (0.5–2.13)	2.07 (0.93–4.64)	1.99 (0.85–4.65)
G2350A
GA/GG	1.65 (1.14–2.40)*	1.93 (1.02–3.63)*	1.02 (0.66–1.56)	1.92 (0.97–3.77)	0.91 (0.49–1.68)
AA/GG	2.04 (1.28–3.28)*	2.41 (1.11–5.22)*	1.13 (0.63–2.04)	2.17 (0.9–5.25)	1.12 (0.5–2.53)
CYP11B2
C-344T
TC/TT	0.75 (0.52–1.07)	0.58 (0.32–1.04)	0.73 (0.48–1.12)	0.50 (0.25–0.99)*	0.82 (0.44–1.55)
CC/TT	1.11 (0.61–2.00)	0.53 (0.16–1.78)	0.75 (0.34–1.68)	1.55 (0.62–3.85)	2.26 (0.99–5.15)

*P < 0.05, ^#adjusted for gender, age, BMI, and smoking status; ^&Others: for example, kidney stone, polycystic kidney disease, and so forth.